Intellectual Disability Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome (FXS)
This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 35 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.
This is a multi-center study at the University of Alberta and CHU Sainte-Justine for fragile X syndrome (FXS) patients aged 6 to 35 years inclusive. It is a randomized, double-blind, placebo-controlled trial of metformin (also known as Glumetza, Glucophage, Fortamet), a type 2 diabetes medication that can also improve obesity and excessive appetite. Metformin has emerged as a candidate drug for the targeted treatment of FXS based on animal studies showing rescue of multiple phenotypes in the FXS model. Metformin may contribute to normalizing signaling pathways in FXS in the central nervous system, which may include activities of mTOR and PI3K, both of which have shown to be pathogenically overactive in FXS. In addition, metformin inhibits phosphodiesterase, which would lead to correction of cAMP levels, and MMP9 production, which is also elevated in FXS. Looking at the potential signaling pathways, metformin appears to be a good candidate for targeting several of the intracellular functions in neurons disrupted in FXS and, therefore, has potential to rescue several types of symptoms in individuals with FXS. Researchers have utilized metformin in the clinical treatment of over 20 individuals with FXS between the ages of 4 and 58 years and have found the medication to be well tolerated and to provide benefits not only in lowering weight gain and normalizing appetite but also in language and behavior. In this controlled trial, the researchers hope to further assess metformin's safety and benefits in the areas of language and cognition, eating and weight loss, and overall behavior. Each participant will be involved in this trial for a period of 4 months. This will include 3 visits to one of the sites and 5 phone calls. At each visit, the researchers will assess behavioral, cognitive, and language development. The researchers will also assess the side effects of the study medication throughout the trial. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05935722 -
Evaluation of a Home-based Parenting Support Program: Parenting Young Children
|
N/A | |
Completed |
NCT04020302 -
Self-Monitoring Shopping Intervention
|
N/A | |
Active, not recruiting |
NCT03548779 -
North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
|
N/A | |
Completed |
NCT03722212 -
Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test
|
N/A | |
Not yet recruiting |
NCT03644797 -
Second Molecular Event Identification by Exome Sequencing for Intellectually Disabled Patients Carrying 16p13.11 CNVs
|
||
Not yet recruiting |
NCT02881333 -
Various Type of Genetic Events in Patients With Intellectual Disability
|
N/A | |
Completed |
NCT03139760 -
POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability
|
N/A | |
Completed |
NCT02746614 -
Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
|
N/A | |
Completed |
NCT06097819 -
Therapy-Based Games' Effects on Motor and Cognitive Skills in Intellectual Disabilities
|
N/A | |
Recruiting |
NCT05767203 -
Genetic Markers and Biomarkers in Patients With Intellectual Disabilities of Genetic Origin
|
N/A | |
Terminated |
NCT05445596 -
Improving Treatment for Children With Intellectual and Developmental Disabilities and Problem Behavior in Schools
|
N/A | |
Recruiting |
NCT05131425 -
Facing Your Fears: Adolescents With ASD and Intellectual Disability
|
N/A | |
Completed |
NCT04436692 -
Dietary Intervention and Adults With Intellectual Disabilities
|
N/A | |
Completed |
NCT04917666 -
Process and Outcomes of Horticultural Therapy for People With Disabilities
|
N/A | |
Completed |
NCT04518358 -
Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills
|
N/A | |
Completed |
NCT04554355 -
Effects of a PA Intervention for Fatness and Fitness in Adolescents With Intellectual Disability
|
N/A | |
Completed |
NCT04277130 -
Effectiveness of Active Video Games in Children With Intellectual Disabilities
|
N/A | |
Enrolling by invitation |
NCT02914951 -
Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability
|
N/A | |
Completed |
NCT02304302 -
Down Syndrome Memantine Follow-up Study
|
Phase 2 | |
Completed |
NCT02591446 -
Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
|
N/A |